CytoSorbents holds a bullish daily structure, yet shorter timeframes do not fully confirm it. The stock closed Friday’s session at $4.11, up 34.31% versus the previous close. That setup stays conditional on daily MACD confirmation and overhead resistance.
Key takeaways
- CytoSorbents closed Friday, October 16, 2026, at $4.11, a gain of 34.31% versus the previous close on volume of 678,400 shares.
- The daily 20-session EMA is $3.76, the 50-session EMA is $3.04, and the 200-session EMA is $1.53, all below the $4.11 close.
- Daily RSI14 is 56.84, above neutral and below overbought; the daily MACD line at 0.06 sits below its signal at 0.24.
- The session close is above the 20-hour EMA at $3.5 and the 50-hour EMA at $3.61, but below the 200-hour EMA at $4.88.
- For the next session, the daily pivot is $3.91, with first resistance at $4.8 and first support at $3.21.
CytoSorbents session: Friday’s price action
CytoSorbents closed Friday’s session at $4.11, a 34.31% gain versus the previous close. CTSO opened at $3.01, traded between a low of $3.01 and a high of $4.60, and closed at $4.11, against a previous close of $3.06.
CTSO opened at $3.01 on Friday, October 16, 2026. It traded between a low of $3.01 and a high of $4.6. Session volume was 678,400 shares.
Meanwhile, a search of recent coverage found no company-specific news behind the move. The chart provides a framework for assessing the setup, but it does not establish the cause.
CytoSorbents daily structure favors bulls, with a momentum caveat
The daily structure favors bulls; however, the daily MACD does not confirm the bias.
CytoSorbents closed above all three daily exponential averages. The 20-session EMA is $3.76, the 50-session EMA is $3.04, and the 200-session EMA is $1.53. Overall, that ordering supports the main bullish bias.
Daily RSI14 stands at 56.84, above neutral but below overbought territory.
Still, the daily MACD line at 0.06 remains below its signal at 0.24. Its histogram is negative at -0.18. This is the central qualification: the daily average structure favors bulls, but MACD does not confirm that bias.
The close sits above the daily Bollinger mid-band at $4.06. Price is between the lower band at $2.85 and the upper band at $5.27. It therefore occupies the upper half of the band structure without exceeding its upper boundary.
Daily ATR14 increased to $0.51 from $0.42. That reading points to greater measured volatility than in the preceding daily candle.
For the next session, the daily pivot sits at $3.91. First resistance is $4.8 and first support is $3.21. These are reference levels when trading resumes, not barriers already tested during the completed session.
Hourly evidence supports price, but not a fully bullish trend
The hourly chart supports price, yet the 200-hour EMA at $4.88 keeps the trend case incomplete.
Meanwhile, the session close sits above the 20-hour EMA at $3.5 and the 50-hour EMA at $3.61. It remains below the 200-hour EMA at $4.88. The averages are not bullishly aligned, leaving a longer-hourly obstacle overhead.
Hourly RSI14 is 65.93, above neutral and below overbought territory. The hourly MACD line at 0.07 is above its signal at -0.05, with a positive histogram of 0.13.
These readings support the bullish daily case. However, they do not remove the resistance represented by the 200-hour EMA.
Notably, the session close also sits above the hourly upper Bollinger band at $4.01. That position supports the positive hourly reading, but it is not sufficient by itself to establish a sustained breakout.
The hourly pivot for the next session is $4.16, above the completed session’s close.
Short-term timing and the two scenarios
Short-term readings are positive, but the bullish case depends on clearing overhead resistance.
15-minute execution context
On the 15-minute chart, price sits above the 200-period EMA at $4.04. It is below the upper Bollinger band at $4.22. RSI14 is 58.89, while the MACD line at 0.2 exceeds its signal at 0.13. These are positive execution readings, not a substitute for daily confirmation. For the next session, the 15-minute pivot is $4.11, with first resistance at $4.39 and first support at $3.77.
Bullish scenario and overhead resistance
The bullish scenario requires holding the daily pivot at $3.91 and clearing the session high at $4.6. Beyond that high, the next reference levels are daily first resistance at $4.8 and the 200-hour EMA at $4.88. A daily MACD line above its signal would provide additional confirmation.
Bearish scenario and lower references
In contrast, a break below $3.91 would undermine that scenario. The 15-minute first support at $3.77 and the daily 20-session EMA at $3.76 would then become important lower references. A break below both would weaken the bullish daily case further, with daily first support at $3.21 below them.
Overall, CytoSorbents stands above its daily pivot reference and key daily averages. It remains below the session high and the 200-hour EMA. Daily ATR14 at $0.51 frames the volatility risk. The unresolved question is whether price can clear overhead resistance while daily MACD supplies the confirmation still missing.
FAQ
Where did CytoSorbents close, and how did the daily averages compare?
CytoSorbents closed Friday’s session at $4.11, a 34.31% gain versus the previous close. That close sits above the daily 20-session EMA at $3.76, the 50-session EMA at $3.04, and the 200-session EMA at $1.53.
What is the key qualification in the daily setup?
The daily MACD line at 0.06 remains below its signal at 0.24, with a negative histogram of -0.18. Daily MACD therefore does not confirm the bullish daily average structure.
Which levels matter for the next session?
The daily pivot is $3.91, with first resistance at $4.8 and first support at $3.21. On the 15-minute chart, the pivot is $4.11, with first resistance at $4.39 and first support at $3.77.
What is the bullish scenario?
The bullish scenario requires holding the daily pivot at $3.91 and clearing the session high at $4.6. Beyond that, the next reference levels are daily first resistance at $4.8 and the 200-hour EMA at $4.88.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.